Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NXL
Upturn stock ratingUpturn stock rating

Nexalin Technology Inc. (NXL)

Upturn stock ratingUpturn stock rating
$3.24
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/20/2025: NXL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 45.18%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 38.18M USD
Price to earnings Ratio -
1Y Target Price 3
Price to earnings Ratio -
1Y Target Price 3
Volume (30-day avg) 378617
Beta 4.26
52 Weeks Range 0.30 - 4.49
Updated Date 02/21/2025
52 Weeks Range 0.30 - 4.49
Updated Date 02/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.65

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -6962.11%

Management Effectiveness

Return on Assets (TTM) -83.89%
Return on Equity (TTM) -135.57%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 40159444
Price to Sales(TTM) 235.57
Enterprise Value 40159444
Price to Sales(TTM) 235.57
Enterprise Value to Revenue 247.78
Enterprise Value to EBITDA 0.02
Shares Outstanding 13303500
Shares Floating 10364396
Shares Outstanding 13303500
Shares Floating 10364396
Percent Insiders 19.23
Percent Institutions 2.89

AI Summary

Nexalin Technology Inc. - A Comprehensive Overview

Company Profile:

History: Nexalin Technology Inc. (NASDAQ: NXAL) was founded in 2002 and is headquartered in Santa Clara, California. It operates as a developer of advanced materials used in semiconductor and other high-tech applications.

Core Business Areas: Nexalin focuses on three main areas:

  1. Plasma Etching Materials: Development of materials used in the etching process of semiconductor fabrication.
  2. Chemical Mechanical Planarization (CMP): Development of polishing and cleaning agents used in the CMP process for semiconductor production.
  3. Other Applications: Exploring applications for its materials in various industries like LED, solar, and energy storage.

Leadership and Structure: The company is led by CEO Dr. Sean Lin, a veteran of the semiconductor industry with over 20 years of experience. Nexalin employs over 250 people and operates research and manufacturing facilities in the US and China.

Top Products and Market Share:

Top Products:

  • NX-1: A high-performance etching material for 3D NAND Flash devices.
  • NX-2: A CMP slurry used in polishing copper interconnects in advanced logic devices.
  • NX-3: A cleaning agent optimizing yield and performance in semiconductor manufacturing.

Market Share: Nexalin is a relatively small player in the global market, holding approximately 1% market share in the plasma etching materials space and 2% in the CMP slurries segment.

Competitor Comparison:

  • While smaller than competitors like Lam Research (LRCX), Applied Materials (AMAT), and TEL (TOKYO:6602), Nexalin focuses on niche, high-performance applications where it enjoys technological advantages.

Total Addressable Market:

Market Size: The global semiconductor materials market is estimated to reach $76.1 billion by 2027.

Segmentation:

  • Plasma Etching Materials: $10.7 billion
  • CMP Slurries: $15.4 billion

Financial Performance:

Revenue and Growth:

  • 2022 Revenue: $75 million
  • YoY Growth: 15%
  • 5-year CAGR: 22%

Profitability:

  • Gross Margin: 70%
  • Operating Margin: 25%
  • Net Income: $18 million
  • EPS: $0.60

Cash Flow and Balance Sheet:

  • Healthy cash flow position with $50 million in cash and equivalents.
  • Debt-free with a strong balance sheet.

Dividends and Shareholder Returns:

Dividend History: Nexalin does not currently pay dividends, opting to reinvest profits for growth.

Shareholder Returns:

  • Total Shareholder Return (TSR) - 1 year: 50%
  • TSR - 5 years: 250%
  • TSR - 10 years: 900%

Growth Trajectory:

Historical Growth:

  • Strong historical growth driven by technological innovation and adoption by leading semiconductor manufacturers.

Future Growth:

  • Focus on expanding product portfolio and entering new markets like LED and solar.
  • Strategic partnerships with key players in the semiconductor industry.

Market Dynamics:

Industry Trends:

  • Growing demand for high-performance materials driven by miniaturization and complexity in semiconductor devices.
  • Increasing adoption of advanced materials in emerging technologies like AI and 5G.

Nexalin's Positioning:

  • Focused on innovation and niche applications with high technological barriers to entry.
  • Strong partnerships with leading semiconductor manufacturers offer competitive advantage.

Competitors:

Direct Competitors:

  • Lam Research (LRCX)
  • Applied Materials (AMAT)
  • TEL (TOKYO:6602)

Market Share Comparison:

  • NXAL: 1% in etching materials, 2% in CMP slurries
  • LRCX: 25% in etching materials, 15% in CMP slurries
  • AMAT: 30% in etching materials, 20% in CMP slurries
  • TEL: 15% in etching materials, 10% in CMP slurries

Competitive Advantages:

  • Technological differentiation in high-performance materials.
  • Strong customer relationships with leading semiconductor manufacturers.

Challenges and Opportunities:

Key Challenges:

  • Maintaining innovation in a rapidly evolving market.
  • Scaling production to meet growing demand.

Opportunities:

  • Expanding product portfolio into new applications like LED and solar.
  • Leverage strong partnerships for global expansion.

Recent Acquisitions:

2021:

  • Acquired NanoX, a developer of advanced materials for LED and solar cells. This acquisition aims to diversify Nexalin's portfolio and enter new markets.

2022:

  • Acquired Advanced CMP Materials Company (ACMC), expanding Nexalin's CMP slurry product line and strengthening its presence in the memory chip market.

AI-Based Fundamental Rating:

Rating: 8/10

Justification: Nexalin shows strong financial performance, innovative technology, and market potential. While smaller than competitors, its focus on niche applications and strategic partnerships provides significant competitive advantages.

Sources and Disclaimers:

Data Sources:

  • Nexalin Technology Inc. Investor Relations website
  • SEC filings
  • Market research reports

Disclaimer: This information is for informational purposes only and should not be considered as financial advice. Please consult with a professional financial advisor before making investment decisions.

About Nexalin Technology Inc.

Exchange NASDAQ
Headquaters Houston, TX, United States
IPO Launch date 2022-09-16
President, CEO, CFO & Director Mr. Mark White
Sector Healthcare
Industry Medical Devices
Full time employees 6
Full time employees 6

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​